A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale (Q38811820)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 October 2016

Language	Label	Description	Also known as
English	A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale	scientific article published on 14 October 2016

Statements

scholarly article

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

1 reference

Europe PubMed Central

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale (English)

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

1 reference

based on heuristic

inferred from title

metastatic breast cancer

1 reference

based on heuristic

inferred from title

Susan M Domchek

3

object named as

Susan M Domchek

1 reference

Europe PubMed Central

4 March 2018

6

object named as

Mark Robson

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

10

object named as

Judy E Garber

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

author name string

Steven J Isakoff

1

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Shannon Puhalla

2

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Michael Friedlander

4

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Bella Kaufman

5

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Melinda L Telli

7

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Véronique Diéras

8

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Hyo Sook Han

9

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Eric F Johnson

11

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

David Maag

12

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Qin Qin

13

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Vincent L Giranda

14

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Stacie P Shepherd

15

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

language of work or name

0 references

publication date

14 October 2016

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Future Oncology

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

13

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

4

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

307-320

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

PARP inhibitors in the management of breast cancer: current data and future prospects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Profile of veliparib and its potential in the treatment of solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Targeting the DNA repair pathway in Ewing sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Poly(ADP-ribose) polymerases in double-strand break repair: focus on PARP1, PARP2 and PARP3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Protein ADP-ribosylation and the cellular response to DNA strand breaks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

The recognition and removal of cellular poly(ADP-ribose) signals.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Structural biology of the writers, readers, and erasers in mono- and poly(ADP-ribose) mediated signaling

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Therapeutic applications of PARP inhibitors: anticancer therapy and beyond

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Role of PARP inhibitors in cancer biology and therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Hereditary breast cancer: new genetic developments, new therapeutic avenues

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Chemotherapy-induced neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Meta-analysis of BRCA1 and BRCA2 penetrance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

The PARP superfamily

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

Role of poly(ADP-ribose) formation in DNA repair

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

22 June 2018

PARP inhibitors attenuate chemotherapy-induced painful neuropathy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

31 August 2018

ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

31 August 2018

Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5618936

31 August 2018

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0412

21 January 2018

Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0412

21 January 2018

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

1 reference

https://api.crossref.org/works/10.2217%2FFON-2016-0412

21 January 2018

BRCA in breast cancer: ESMO Clinical Practice Guidelines

1 reference

https://pubmed.ncbi.nlm.nih.gov/27739325

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.2217/FON-2016-0412

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

1 reference

Europe PubMed Central

4 March 2018

http://europepmc.org/abstract/PMC/5618936

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38811820&oldid=1788158287"